Publication:
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate

Simple item page
dc.contributor.authorHerrero Ezquerro, María Trinidad
dc.contributor.authorYuste Lucas, Juan Luis
dc.contributor.authorCuenca Bermejo, Lorena
dc.contributor.authorAlmela Rojo, Pilar
dc.contributor.authorArenas-Betancur, L.
dc.contributor.authorDe Pablos, V.
dc.contributor.authorGonzález Cuello, Ana María
dc.contributor.authorDel Bel, E.
dc.contributor.authorNavarro Zaragoza, Javier
dc.contributor.authorFernández Villalba, Emiliano
dc.contributor.departmentAnatomía
dc.date.accessioned2024-02-09T09:18:29Z
dc.date.available2024-02-09T09:18:29Z
dc.date.issued2023-03
dc.description©2023. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ This document is the Submitted, Accepted, Published, version of a Published Work that appeared in final form in Open Biology. To access the final edited and published work see https://doi.org/10.1098/rsob.220370
dc.description.abstractNitric oxide (NO) plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). The objective of this study was to ascertain whether the NO synthase inhibitor, 7-nitroindazole (7-NI), is able to reduce L-DOPA induced dyskinesias (LIDs) in a non-human primate model of PD chronically intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Six Parkinsonian macaques were treated daily with L-DOPA for 3–4 months until they developed LIDs. Three animals were then co-treated with a single dose of 7-NI administered 45 min before each L-DOPA treatment. Dyskinetic MPTP-treated monkeys showed a significant decrease in LIDs compared with their scores without 7-NI treatment ( p < 0.05). The anti-Parkinsonian effect of L-DOPA was similar in all three monkeys with and without 7-NI co-treatment. This improvement was significant with respect to the intensity and duration of LIDs while the beneficial effect of L-DOPA treatment was maintained and could represent a promising therapy to improve the quality of life of PDpatients.
dc.formatapplication/pdfes
dc.format.extent7es
dc.identifier.citationOpen Biology 13: 220370
dc.identifier.doihttps://doi.org/10.1098/rsob.220370
dc.identifier.issn2046-2441
dc.identifier.urihttp://hdl.handle.net/10201/139065
dc.languageenges
dc.publisherThe Royal Society Publishinges
dc.relationM.T.H. holds grants related with the topic of this research from the Spanish Ministry of Science (SAF 2007-62262), Fundación Séneca (FS/15329/PI/10) and own projects.es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectParkinson's Diseasees
dc.subjectDiskynesiases
dc.title7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primatees
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
relation.isAuthorOfPublication9bbe7af5-429b-4029-b621-0399a6838322
relation.isAuthorOfPublication6ceb186d-28b7-4cdf-8f44-b4a2c71b2f29
relation.isAuthorOfPublication80cb2f28-f9ff-4190-8ac0-a4773288c0d3
relation.isAuthorOfPublication5028b798-617b-4311-8389-11b8f71ac210
relation.isAuthorOfPublication2ffc1f4a-bc68-494a-853c-202363b39364
relation.isAuthorOfPublication91a9c0cf-0115-4c34-9b53-72a417c2d883
relation.isAuthorOfPublication072da45c-404e-4559-a637-6e8df94220c7
relation.isAuthorOfPublication.latestForDiscovery9bbe7af5-429b-4029-b621-0399a6838322
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2023_7Nitroindazole-reduces-LDOPAinduced-dyskinesias-in-nonhuman-Parkinsonian-primateOpen-Biology.pdf
Size:
799.55 KB
Format:
Adobe Portable Document Format
Description:
Dyskinesias Parkinson's
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos